Clinical trial
Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG-Nanodosing: the Path to Higher Sensitivity and Lower Toxicity Radiopharmaceuticals
NCT01730417 is registered in ClinicalTrials.gov with Bennett Chin as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG-Nanodosing: the Path to Higher Sensitivity and Lower Toxicity Radiopharmaceuticals
- Lead sponsor
- Bennett Chin
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2009
- Completion date
- July 31, 2011
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.